You are here
Arrayit Corporation Announces Brands Expansion of Proprietary Finger Stick Allergy Testing
Sunnyvale, Nov. 05, 2018 (GLOBE NEWSWIRE) -- Arrayit Corporation (OTC: ARYC), a life sciences and personalized medicine company, announces expansion of its proprietary finger stick microarray allergy testing platform to a growing number of major market brands. Highly automated Arrayit technology is inherently suited to leveraging multiple brands and their unique venues and relationships to reach a larger number of allergy patients more quickly. Each brand serving major retail chains, large government agencies, medical clinics and doctor offices receive the same high-level testing support and treatment options through the company’s Patient Data Solutions (PDS) on-line allergy testing portal and therapeutics affiliates. Arrayit allergy brands expansion is increasingly allowing the 250,000 primary care physicians in the United States to more accurately diagnose and treat an estimated 60,000,000 (60 million) American allergy patients.
Arrayit recently completed an allergy testing pilot program for a top retail chain, established a nationwide network of 1,700 allergy sales professionals, met with top officials at the United States Food and Drug Administration (FDA) regarding approval of a major product line, signed allergy testing contracts with a consortium of 178 medical clinics, received approval for in-store promotions by a major retailer, announced allergy testing partnerships with major allergy therapeutics providers, received approval for direct Medicare billing by the Centers for Medicare and Medicaid Services (CMS), reported the sale and shipping of clinical instrumentation to the FDA, aced three consecutive rounds of proficiency testing with the College of American Pathologists, launched the Patient Data Solutions allergy portal for doctors and clinics, and celebrated 25 years of company operations. Allergy brands expansion relies on simple, convenient and non-invasive finger stick blood sampling to measure allergy- and asthma-related immunoglobulin E (IgE) molecules in newborns, special needs children, seniors, military personnel, Medicare and Medicaid patients, and the general public.
Chief Executive Officer Rene Schena states, “Brands expansion of our allergy testing products represents a dynamic step towards delivering quantitative, actionable allergy test results to doctors treating patients nationwide. Early detection of allergy and asthma on a personalized and family-centric basis provides an excellent value proposition with respect to preventative medicine, improved healthcare and greater wellness.”
Arrayit Corporation, headquartered in Sunnyvale, California, leads and empowers the research, biotechnology, pharmaceutical, clinical and healthcare sectors through the discovery, development and manufacture of proprietary life science and personalized medicine products and services to advance biomedical research and improve wellness and human health. Please visit www.arrayit.com for more information.
Safe Harbor Statement
We have identified forward-looking statements by using words such as "expect", "believe", and "should". Although we believe our expectations are reasonable, our operations involve a number of risks and uncertainties that are beyond our control, and these statements may turn out not to be true. Risk factors associated with our business, including some of the facts set forth herein, are detailed in the Company's public filings.
CONTACT: CONTACT Public Relations Arrayit Corporation Tel: 408-744-1331 Email: email@example.com Web: www.arrayit.com